Albumin-Bound Paclitaxel clinical trials
Also written Abraxane and ABI-007.
Its developmentBy 11 companies, company by company51 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.A product of Paclitaxel; its studies count on that page too.
How each study uses Albumin-Bound Paclitaxel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Albumin-Bound Paclitaxel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 7 Jan 2005 · ABRAXANE · NDA 021660 (FDA, Drugs@FDA)
- European Union
- 11 Jan 2008 · Abraxane · EMEA/H/C/000778 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Abraxane
- 209
Studies by the year they started
526 studies that test it; most in 2019 (41); 1 more planned to start later
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 11 |
| 2006 | 18 |
| 2007 | 18 |
| 2008 | 26 |
| 2009 | 10 |
| 2010 | 10 |
| 2011 | 12 |
| 2012 | 21 |
| 2013 | 25 |
| 2014 | 36 |
| 2015 | 35 |
| 2016 | 21 |
| 2017 | 25 |
| 2018 | 20 |
| 2019 | 41 |
| 2020 | 30 |
| 2021 | 28 |
| 2022 | 30 |
| 2023 | 24 |
| 2024 | 24 |
| 2025 | 26 |
| 2026 | 26 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 85 · Other 442
Celgene (28) · Fudan University (26) · Sun Yat-sen University (11) · M.D. Anderson Cancer Center (11) · City of Hope Medical Center (9) · Tianjin Medical University Cancer Institute and Hospital (9) · UNC Lineberger Comprehensive Cancer Center (8) · Chinese PLA General Hospital (8)
Often tested with
Tested in the same studies.
Gemcitabine (157) · Carboplatin (73) · Cisplatin (56) · Bevacizumab (31) · Tegafur (19) · Trastuzumab (18) · Cyclophosphamide (18) · Gimeracil (18)
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Paclitaxel source
- One of Antimitotic agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 28 phase 3 studies under way
Albumin-Bound Paclitaxel is the comparator. A study of two new drugs counts under both.
- 5Sacituzumab tirumotecan · Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · next primary completion Apr 2027
- 3Sacituzumab govitecan · Gilead Sciences · next primary completion Feb 2027
- 3Izalontamab brengitecan · Sichuan Baili Pharmaceutical Co., Ltd., Bristol-Myers Squibb · next primary completion Mar 2028
- 2Datopotamab deruxtecan · AstraZeneca · next primary completion Jul 2027
- 1Trastuzumab pamirtecan · DualityBio Inc.
- 1Trastuzumab rezetecan · Jiangsu HengRui Medicine Co., Ltd.
- 1Daraxonrasib · Revolution Medicines, Inc.
- 1Trastuzumab deruxtecan · AstraZeneca
Reaching primary completion within a year · 36, 1 in phase 3
Studies that test Albumin-Bound Paclitaxel, phase 3 first.
- May 2027A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerPhase 3 · Akeso
- Nov 2026Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell CarcinomaPhase 2 · Ruijin Hospital
- Nov 2026A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerPhase 2 · The First Affiliated Hospital of Zhengzhou University
- Dec 2026A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract CancerPhase 2 · AHS Cancer Control Alberta
- Dec 2026A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic CancerPhase 1 · Abramson Cancer Center at Penn Medicine
- Dec 2026Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic CancerPhase 2 · SynerGene Therapeutics, Inc.
- Dec 2026Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyPhase 2 · Zhejiang Cancer Hospital
- Dec 2026A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCCPhase 2 · Beijing Tongren Hospital
- Dec 2026AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerPhase 1/2 · Akeso
- Dec 2026Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerPhase 2 · Tianjin Medical University Second Hospital
Studies
Open first, then newest update. How each study uses Albumin-Bound Paclitaxel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 527
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07491445Written as nab-paclitaxelHow we know
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Nab-paclitaxelHow we know
- Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesRecruitingPhase 1City of Hope Medical CenterNCT06675136Written as Nab-paclitaxelHow we know
- Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerRecruitingPhase 2Loma Linda UniversityNCT03492671Written as nab-paclitaxelHow we know
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Nab-PaclitaxelHow we know
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as nab-paclitaxelHow we know
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Nab-paclitaxelHow we know
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Peking University People's HospitalNCT07885709Written as Nab-paclitaxelHow we know
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingPhase 3German Cancer Research CenterNCT07877584Written as nab-Paclitaxel (100 mg/m² )How we know
- Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingPhase 2Georgetown UniversityNCT06423326Written as Nab-paclitaxelHow we know
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingPhase 2Wake Forest University Health SciencesNCT05825066Written as Nab paclitaxelHow we know
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingPhase 2Wake Forest University Health SciencesNCT04253964Written as Nab paclitaxelHow we know
- Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Northwell HealthNCT07163273Written as Gemcitabine plus nab-Paclitaxel (GnP)How we know
- A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung CancerRecruitingPhase 2People's Hospital of QuzhouNCT07647094Written as Serplulimab, Nab-Paclitaxel, CarboplatinHow we know
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 2Corcept TherapeuticsNCT07259317Written as Nab-paclitaxelHow we know
- Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07831330Written as Albumin-bound Paclitaxel (Ⅱ) + GemcitabineHow we know
- Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 2University of MiamiNCT07096362Written as Nab PaclitaxelHow we know
- Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07828756Written as Albumin-bound Paclitaxel (Ⅱ)How we know
- Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.Not yet recruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07808567Written as GnPHow we know
- Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingPhase 3Gruppo Oncologico del Nord-OvestNCT06897644Written as Nab-paclitaxelHow we know
See all 527 studies that test Albumin-Bound Paclitaxel →
Given beside what is tested · 595 — Albumin-Bound Paclitaxel is usual care or a partner of the new treatment
- Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05422794Written as Nab-paclitaxelHow we know
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Nab-paclitaxelHow we know
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Nab-paclitaxelHow we know
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)RecruitingPhase 1/2Eddingpharm (Zhuhai) Co., Ltd.NCT07738341Written as Nab-PaclitaxelHow we know
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingPhase 3Merck Sharp & Dohme LLCNCT06422143Written as Nab-paclitaxelHow we know
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruitingPhase 2Corcept TherapeuticsNCT06906341Written as Nab-paclitaxel 80 mg/m^2How we know
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingPhase 2/3Eikon TherapeuticsNCT07365319Written as Nab-paclitaxel + CarboplatinHow we know
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07793942Written as Nab-paclitaxelHow we know
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07024615Written as Nab-paclitaxelHow we know
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Nab-paclitaxelHow we know
- A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07221474Written as Nab-paclitaxelHow we know
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2ExelixisNCT07845786Written as Nab-paclitaxelHow we know
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Gemcitabine + Nab-paclitaxelHow we know
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDACRecruitingPhase 1/2West China HospitalNCT07802184Written as Nab-paclitaxelHow we know
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingPhase 1/2Inhibrx Biosciences, IncNCT04198766Written as Nab paclitaxel 100mg/m2How we know
- A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line TherapyRecruitingPhase 1/2Shenzhen Majory Biotechnology Co., Ltd.NCT07235202Written as Nab-paclitaxelHow we know
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as Nab-paclitaxelHow we know
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast CancerRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT06802757Written as Nab-paclitaxelHow we know
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07432594Written as Albumin-Bound Paclitaxel /nab-PaclitaxelHow we know
- A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Written as Nab-paclitaxelHow we know
Showing 20 of 595.
As the comparator · 56 — what is tested is compared with Albumin-Bound Paclitaxel
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Nab-paclitaxelHow we know
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Immuneering CorporationNCT07562152Written as GnPHow we know
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Nab-paclitaxelHow we know
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as Albumin-Bound PaclitaxelHow we know
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tianjin Medical University Second HospitalNCT07879469Written as Toripalimab and Nab-PaclitaxelHow we know
- A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06731907Written as Nab-paclitaxelHow we know
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312176Written as Nab-paclitaxelHow we know
- A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersRecruitingPhase 2AbbVieNCT07769502Written as Nab-PaclitaxelHow we know
- A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07729956Written as Nab-paclitaxelHow we know
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingPhase 3AstraZenecaNCT06103864Written as Nab-paclitaxelHow we know
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerRecruitingPhase 2/3HutchmedNCT06361888Written as Nab-paclitaxel Plus GemcitabineHow we know
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerRecruitingPhase 3NRG OncologyNCT06958328Written as Nab-paclitaxelHow we know
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingPhase 2/3Bristol-Myers SquibbNCT06926868Written as Nab-paclitaxelHow we know
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07648914Written as Albumin-Bound PaclitaxelHow we know
- SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerNot yet recruitingPhase 2/3Shanghai Chest HospitalNCT07662811Written as Nab-PaclitaxelHow we know
- A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyRecruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07071337Written as Nab-paclitaxelHow we know
- Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic CancerRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07238283Written as nab-paclitaxel; gemcitabineHow we know
- A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07040644Written as Nab-paclitaxelHow we know
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06255392Written as Paclitaxel-albuminHow we know
- Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic CancerRecruitingPhase 3Fudan UniversityNCT06250972Written as Gemcitabine, Nab-paclitaxel, IrinotecanHow we know
Showing 20 of 56.
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered2
- Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal CarcinomaNov 5, 2026NCT07920250
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCOct 21, 2026NCT07885709